133 related articles for article (PubMed ID: 3446223)
21. Cholecystokinin receptor antagonism by peptidergic and non-peptidergic agents in rat pancreas.
Dembinski A; Jaworek J; Konturek PK; Konturek SJ; Warzecha Z
J Physiol; 1989 Apr; 411():419-35. PubMed ID: 2614728
[TBL] [Abstract][Full Text] [Related]
22. CR-1409: a potent inhibitor of cholecystokinin-stimulated amylase release and cholecystokinin binding in rat pancreatic acini.
Iwamoto Y; Yamamoto R; Kuzuya T
Pancreas; 1987; 2(1):85-90. PubMed ID: 2437574
[TBL] [Abstract][Full Text] [Related]
23. Effect of cholecystokinin receptor antagonist on pancreatic responses to exogenous gastrin and cholecystokinin and to meal stimuli.
Konturek SJ; Tasler J; Cieszkowski M; Szewczyk K; Hladij M
Gastroenterology; 1988 Apr; 94(4):1014-23. PubMed ID: 3345871
[TBL] [Abstract][Full Text] [Related]
24. Effect of L-364,718 on GRP-stimulated pancreatic and gastric secretions and GI peptides in conscious dogs.
Hosotani R; Chowdhury P; Huang YS; McKay D; Yajima H; Rayford PL
Pancreas; 1989; 4(5):550-5. PubMed ID: 2813326
[TBL] [Abstract][Full Text] [Related]
25. Effect of a cholecystokinin antagonist, proglumide, on cholecystokinin-8-induced gallbladder contraction in conscious dogs.
Fujimura M; Sakamoto T; Lluis F; Beauchamp RD; Townsend CM; Greeley GH; Thompson JC
Biol Signals; 1992; 1(2):94-100. PubMed ID: 1307918
[TBL] [Abstract][Full Text] [Related]
26. Inhibitory effects of the cholecystokinin antagonist loxiglumide on pancreatic exocrine secretion and pancreatic growth in conscious rats.
Taguchi S; Green GM; Nakano I; Hatta Y
Int J Pancreatol; 1992 Apr; 11(2):67-73. PubMed ID: 1607730
[TBL] [Abstract][Full Text] [Related]
27. Cholecystokinin is a physiological regulator of gastric acid secretion in man.
Burckhardt B; Delco F; Ensinck JW; Meier R; Bauerfeind P; Aufderhaar U; Ketterer S; Gyr K; Beglinger C
Eur J Clin Invest; 1994 Jun; 24(6):370-6. PubMed ID: 7957488
[TBL] [Abstract][Full Text] [Related]
28. Role of cholecystokinin in canine pancreatic exocrine response to bombesin stimulation.
Nealon WH; Beauchamp RD; Townsend CM; Thompson JC
Am J Surg; 1987 Jan; 153(1):96-101. PubMed ID: 3799899
[TBL] [Abstract][Full Text] [Related]
29. L-364,718, a new CCK antagonist, inhibits postprandial pancreatic secretion and PP release in dogs.
Hosotani R; Chowdhury P; Rayford PL
Dig Dis Sci; 1989 Mar; 34(3):462-7. PubMed ID: 2646088
[TBL] [Abstract][Full Text] [Related]
30. Cholecystokinin is a regulator of intestinal phase-stimulated PP release.
Adler G; Beglinger C; Braun U; Reinshagen M; Koop I; Schafmayer A
Regul Pept; 1990 Sep; 30(2):105-11. PubMed ID: 2274676
[TBL] [Abstract][Full Text] [Related]
31. Role of cholecystokinin in pancreatic exocrine response to intraluminal amino acids and fat.
Stubbs RS; Stabile BE
Am J Physiol; 1985 Mar; 248(3 Pt 1):G347-52. PubMed ID: 2858160
[TBL] [Abstract][Full Text] [Related]
32. Bioactivity of synthetic human cholecystokinin (CCK)-33 in vitro and in vivo.
Shinozaki H; Miyasaka K; Wakasugi H; Fujii N; Funakoshi A
Gastroenterol Jpn; 1991 Feb; 26(1):51-5. PubMed ID: 1706670
[TBL] [Abstract][Full Text] [Related]
33. Effect of CCK antagonists CR 1409 and CR 1505 on rat pancreatic exocrine secretion in vivo.
Shiratori K; Shimizu K; Watanabe S; Takeuchi T; Moriyoshi Y
Pancreas; 1989; 4(6):744-50. PubMed ID: 2813333
[TBL] [Abstract][Full Text] [Related]
34. Effect of the cholecystokinin-receptor antagonist lorglumide on pancreatic enzyme secretion stimulated by bombesin, food, and caerulein, giving similar plasma cholecystokinin concentrations in the dog.
de Jong AJ; Singer MV; Jansen JB; Niebel W; Rovati LC; Lamers CB
Gut; 1991 Feb; 32(2):215-9. PubMed ID: 1864545
[TBL] [Abstract][Full Text] [Related]
35. Effect of a novel cholecystokinin receptor antagonist, FK480, administered intraduodenally, on pancreatic secretion in rats.
Moriyoshi Y; Shiratori K; Takeuchi T; Watanabe S
Pancreas; 1995 Apr; 10(3):295-300. PubMed ID: 7542771
[TBL] [Abstract][Full Text] [Related]
36. Effect of a cholecystokinin antagonist on meal-stimulated insulin and pancreatic polypeptide release in humans.
Hildebrand P; Ensinck JW; Ketterer S; Delco F; Mossi S; Bangerter U; Beglinger C
J Clin Endocrinol Metab; 1991 May; 72(5):1123-9. PubMed ID: 2022712
[TBL] [Abstract][Full Text] [Related]
37. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo.
Scarpignato C; Kisfalvi I; D'Amato M; Varga G
Aliment Pharmacol Ther; 1996 Jun; 10(3):411-9. PubMed ID: 8791971
[TBL] [Abstract][Full Text] [Related]
38. Comparison of loxiglumide, a cholecystokinin receptor antagonist, and atropine on hormonal and meal-stimulated pancreatic secretion in man.
Gabryelewicz A; Kulesza E; Konturek SJ
Scand J Gastroenterol; 1990 Jul; 25(7):731-8. PubMed ID: 2396088
[TBL] [Abstract][Full Text] [Related]
39. In vitro and in vivo effect of proglumide on cholecystokinin-stimulated amylase release in mouse pancreatic acini.
Iwamoto Y; Nakamura R; Akanuma Y
Gastroenterol Jpn; 1984 Feb; 19(1):53-8. PubMed ID: 6202584
[TBL] [Abstract][Full Text] [Related]
40. Pancreatic growth: interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice.
Niederau C; Liddle RA; Williams JA; Grendell JH
Gut; 1987; 28 Suppl(Suppl):63-9. PubMed ID: 2446964
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
